Sector News

Novo's new CEO confides that M&A will be part of growth search

March 13, 2017
Life sciences

Denmark’s Novo Nordisk surprised some folks when it selected Lars Fruergaard Jorgensen as its new CEO. Now Jorgensen is surprising others with a new strategy for taking the staid pharma player into M&A for growth.

The company has already recast its R&D to look at areas that are ancillary to its core business in diabetes. Jorgensen acknowledged in an interview with Reuters that the company needs to do some “bolt on” deals that can expand on that strategy.

“It is not my ambition to go out and do deals where we would not be bringing significant value in terms of disease understanding, commercial infrastructure or manufacturing. The more of those boxes you can tick the better,” Jorgensen explained.

He would not comment about a report last week from Reuters that Novo is scoping out blood therapy biotech Global Blood Therapeutics (GBT). The California biotech is working in sickle cell anemia as well as other areas. GBT, which saw its stock jump 2% on the news, has a market cap of about $1.4 billion.

He did acknowledge that it needed to find some deals to help with growth. “Across our business we need to increasingly look for external innovation,” he told Reuters.

Jorgensen, who took on the CEO mantle Jan. 1, comes on at very difficult time for the drugmaker. Novo has seen its growth stymied by a very competitive diabetes market that has allowed U.S. payers to work exclusive deals to cut their costs. The drugmaker has offered very weak forecasts for the year. It has also laid off 1,000 employees in the U.S. to cut costs.

On top of all of that, its history of price hikes has also drawn Congressional scrutiny and legal action from both investors and consumers. A class action lawsuit by a retirement fund alleged the company hid price-fixing in the insulin market. That was followed by legal action from consumers who made similar claims against Novo and competitors Sanofi and Lilly, saying the companies made “astounding” insulin price increases.

Novo was counting on veteran exec Jakob Riis, who was named last fall to head of North American operations, to negotiate the company’s path through the difficult U.S. environment. But Riis was among those most surprised by the appointment of Jorgensen. He recently resigned, acknowledging that he left in disappointment over not being named to the top spot himself.

It is not as if Novo is completely adrift in the U.S. Despite the payer pressures, that region delivered 4% growth last year, a 37% share of the company’s overall expansion. But with payer and political pressures mounting, the company has projected overall sales growth for the year of -1% to 4% in local currencies,translating to 1% to 6% on a reported basis.

By Eric Palmer

Source: Fierce Pharma

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”